jcm-logo

Journal Browser

Journal Browser

Diagnosis and Treatment of Gastrointestinal Malignancies

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Oncology".

Deadline for manuscript submissions: 20 February 2026 | Viewed by 51

Special Issue Editors


E-Mail Website
Guest Editor
Medical Oncology, AO S. Croce e Carle, 12100 Cuneo, Italy
Interests: gastrointestinal cancers; immunotherapy; targeted therapy; chemotherapy; microsatellite instability; driver mutations
Special Issues, Collections and Topics in MDPI journals

E-Mail
Guest Editor
Medical Oncology, Azienda Ospedaliera S.Croce e Carle, Cuneo, Italy
Interests: supportive care; health services research; gastrointestinal cancers

Special Issue Information

Dear Colleagues,

This Special Issue on “Diagnosis and Treatment of Gastrointestinal Malignancies” will mainly focus on analyzing present and future approaches for the treatment of gastrointestinal (GI) cancer patients, with a glimpse of novel perspectives and future challenges in clinical practice. GI cancers are one of the most common causes of cancer-related death worldwide. They include a very wide spectrum of neoplasms, such as esophageal, gastric, hepatic, biliary, pancreatic, small bowel, and large bowel, as well as rectal cancers. In the last decade, significant improvements have been made in the prognosis of patients affected by these tumors thanks to the development of new treatments, which include cytotoxic drugs, targeted therapies, and immunotherapy. Recently, emerging and novel biomarkers have been identified and validated, with a huge impact on patient outcomes and improving the treatment landscape. Despite these advances, GI cancers still represent a major public health problem worldwide; hence, it is mandatory to develop novel therapeutic approaches. We cordially invite experts in the field to submit original research or review articles to deepen the knowledge about this important topic.

We look forward to receiving your contributions.

Dr. Carmelo Laface
Dr. Gianmauro Numico
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gastrointestinal cancers
  • immunotherapy
  • targeted therapy
  • chemotherapy
  • microsatellite instability
  • driver mutations

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 535 KiB  
Article
Comparison of Frontline FOLFIRINOX with Fluorouracil-Based and Gemcitabine-Based Chemotherapies in Metastatic Ampullary Adenocarcinoma: A Multicenter Study by the Turkish Oncology Group (TOG)
by Ali Kalem, Tulay Kus, Savas Gokcek, Ilkay Tugba Unek, Taha Koray Sahin, Omer Dizdar, Muhammed Fatih Sagıroglu, Hatice Bolek, Yuksel Urun, Sendag Yaslıkaya, Ertugrul Bayram, Nadiye Sever, Ibrahim Vedat Bayoğlu, Omer Acar, Atike Pınar Erdogan, Seray Saray, Berkan Karabuga, Ulku Arslan Yalcıntas, Safa Can Efil, Mehmet Ali Nahit Sendur, Talat Aykut, Murat Araz, Tugce Kubra Gunes, Melike Ozcelik, Mustafa Seyyar, Gokmen Aktas and Suayib Yalcınadd Show full author list remove Hide full author list
J. Clin. Med. 2025, 14(16), 5868; https://doi.org/10.3390/jcm14165868 (registering DOI) - 20 Aug 2025
Abstract
Background: Adenocarcinoma arising from the ampulla of Vater is an extremely rare neoplasm, and there are limited data regarding frontline therapy for metastatic disease. We investigated the outcomes of first-line treatment with FOLFIRINOX by comparing it with other treatments in patients with advanced [...] Read more.
Background: Adenocarcinoma arising from the ampulla of Vater is an extremely rare neoplasm, and there are limited data regarding frontline therapy for metastatic disease. We investigated the outcomes of first-line treatment with FOLFIRINOX by comparing it with other treatments in patients with advanced ampullary adenocarcinoma. Methods: We included 123 patients with advanced ampullary adenocarcinoma who were treated with frontline FOLFIRINOX (n = 32), fluorouracil (FU)-based chemotherapy (n = 20), and gemcitabine-based chemotherapy (n = 65) between August 2007 and January 2024 in this retrospective study. The median progression-free survival (mPFS) and overall survival (mOS) according to treatment and clinicopathological features were calculated using the Kaplan–Meier method. Results: The median age of the patients was 62 years (range, 36–78), and 75,6% of the patients had an ECOG performance status of 0–1. The mOS were 13 months (95% CI, 10.6–14.4), 11 months (95% CI, 10.6–14.4), and 12 months (95% CI, 10.6–14.4), respectively [p = 0.865]. There were no significant differences in OS among the chemotherapeutic agents according to histological subtypes. However, FOLFIRINOX and FU-based treatments appeared more effective in the intestinal subtype, while gemcitabine-based therapies were less effective. In the pancreaticobiliary subtype, FU-based therapies yielded a shorter outcome compared to FOLFIRINOX and gemcitabine-based therapies. Grade 3 or 4 hematologic toxicities were higher in patients treated with FOLFIRINOX. Conclusions: In advanced ampullary adenocarcinoma, despite higher toxicity, frontline FOLFIRINOX showed a trend toward an OS benefit in the intestinal subtype while providing a similar outcome in the pancreaticobiliary subtype. Full article
(This article belongs to the Special Issue Diagnosis and Treatment of Gastrointestinal Malignancies)
Show Figures

Figure 1

Back to TopTop